Pantziarka P et al., 2014-07-10: The ReDO review that organised the preclinical mebendazole evidence and flagged two human case reports, proposing combinations with existing chemotherapy and further trials. It is the document that carried the repurposing case to a clinical audience.
Mebendazole, a well-known anti-helminthic drug in wide clinical use, has anti-cancer properties that have been elucidated in a broad range of pre-clinical studies across a number of different cancer types. Significantly, there are also two case reports of anti-cancer activity in humans.
abstract
Pantziarka P et al., 2014-07-10: The ReDO review that organised the preclinical mebendazole evidence and flagged two human case reports, proposing combinations with existing chemotherapy and further trials. It is the document that carried the repurposing case to a clinical audience. Study type: narrative review by a not-for-profit repurposing consortium. Country: Belgium (Anticancer Fund) and United States (GlobalCures). No subjects of its own. Competing interests as printed: 'The authors declare that they have no competing interests. All the authors are associated with not-for-profit organisations that aim to repurpose drugs for oncology treatments.' Affiliations: Anticancer Fund (Brussels), The George Pantziarka TP53 Trust (London), GlobalCures Inc (Newton, MA), Beth Israel Deaconess/Harvard. The 'two case reports' are not named in the abstract; the full text lists them. Funding: not stated in the article's competing-interests section; authors are salaried by the named not-for-profits. Also filed as MBD-18 (claims C4, C7).
